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Abstract
Invasive fusariosis (IF) has been associated with a poor prognosis. Although recent series have reported improved outcomes, the deﬁnition of
optimal treatments remains controversial. The objective of this studywas to evaluate changes in the outcomeof IF.We retrospectively analysed
233 cases of IF from 11 countries, comparing demographics, clinical ﬁndings, treatment and outcome in two periods: 1985–2000 (period 1) and
2001–2011 (period 2). Most patients (92%) had haematological disease. Primary treatment with deoxycholate amphotericin B was more
frequent in period 1 (63% vs. 30%, p <0.001), whereas voriconazole (32% vs. 2%, p <0.001) and combination therapies (18% vs. 1%, p <0.001)
weremore frequent in period 2. The 90-day probabilities of survival in periods 1 and 2were 22% and 43%, respectively (p <0.001). In period 2,
the 90-day probabilities of survival were 60% with voriconazole, 53% with a lipid formulation of amphotericin B, and 28% with deoxycholate
amphotericin B (p 0.04). Variables associated with poor prognosis (death 90 days after the diagnosis of fusariosis) by multivariable analysis
were: receipt of corticosteroids (hazard ratio (HR) 2.11, 95% CI 1.18–3.76, p 0.01), neutropenia at end of treatment (HR 2.70, 95% CI 1.57–
4.65, p <0.001), and receipt of deoxycholate amphotericin B (HR 1.83, 95% CI 1.06–3.16, p 0.03). Treatment practices have changed over the
last decade, with an increased use of voriconazole and combination therapies. There has been a 21% increase in survival rate in the last decade.
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Introduction
Invasive fusariosis (IF) is a leading mycosis affecting immuno-
compromised patients [1]. The disease is usually invasive and
disseminated, affecting mostly neutropenic patients with acute
leukaemia [2] or patients with severe T-cell immunodeﬁciency,
especially haematopoietic cell transplant recipients receiving
corticosteroids for the treatment of severe graft-versus-host
disease (GVHD) [3]. Most infections in humans are caused by
Fusarium solani species complex and Fusarium oxysporum
species complex [1].
The treatment of IF is limited by the fact that most Fusarium
species show high MICs for the antifungal agents available,
including the extended-spectrum azoles voriconazole and
posaconazole [1]. The previously reported prognosis of IF in
immunocompromised patients is very poor, with 90-day
survival rates of only 21% in patients with haematological
malignancies [2] and 13% in haematopoietic cell transplant
recipients [3]. However, recent data have suggested that the
outcome of IF has improved [4,5].
In this study, we analysed a large series of cases of IF,
encompassing patients diagnosed between 1985 and 2011, to
determine whether the outcome of IF has indeed improved.
We also sought to identify changes in the epidemiology, clinical
presentation, diagnostic procedures, and therapeutic practices,
and to identify predictors of poor outcome.
Methods
This was a retrospective analysis of cases of IF from different
parts of the world. Four databases were merged: the ﬁrst
database collected cases of IF from 12 Brazilian centres and
two centres in the USA; the second (FungiScope—A Global
Registry for Emerging Fungal Infections) collected cases from
different parts of the world; the third collected data from the
Pﬁzer voriconazole clinical database; and the fourth collected
cases from the French National Reference Centre for Invasive
Mycoses and Antifungals [5]. The study was approved by the
Ethics Committee of participating centres. A case report form
was designed in order to accommodate differences in the
original databases. Three authors (M.J.G.T.V., P.F.T., and M.N.)
reviewed the deﬁnitions of each variable contained in the
original databases, in order to ensure consistency in the
process of merging. We collected data regarding demograph-
ics, underlying disease and its treatment, details of haemato-
poietic cell transplantion, including donor type, stem cell
source, the presence and severity of GVHD, and receipt of
corticosteroids (in the 15 days preceding the diagnosis of IF),
neutropenia (<500/mm3), clinical manifestations of IF, diagno-
sis, the species causing infection, treatment, and outcome
(90-day survival). Disseminated fusariosis was deﬁned as the
involvement of more than one non-contiguous organ. Cases of
fungaemia were not deﬁned as disseminated disease unless
another organ was involved (e.g. skin, lung, or sinuses).
All cases were reviewed by one of the authors (M.N.)
blinded to treatment and time period, and classiﬁed as proven
or probable IF according to the modiﬁed European Organi-
zation for Treatment and Research of Cancer/Mycosis Study
Group criteria [6]. Cases of possible fusariosis and of
non-invasive infection were excluded.
For the purpose of this analysis, we arbitrarily established two
time periods: 1985–2000 (period 1) and 2001–2011 (period 2).
Demographics, underlying diseases and their treatment, neu-
tropenia, receipt of corticosteroids, clinical manifestations,
diagnostic procedures, treatment and outcome (90-day survival)
were compared over the two periods. In addition, we assessed
factors associated with 90-day survival in period 2, to evaluate
the effects of different treatments on the outcome. For this
analysis, cases in which no treatment was given were excluded.
The following variables were evaluated by univariate and
multivariable Cox regression analysis: age, gender, country
(Brazil vs. others andUSAvs. others), underlying disease, receipt
of corticosteroids, neutropenia at diagnosis of fusariosis and at
end of treatment, clinical manifestations, and primary treatment
(deoxycholate amphotericin B, lipid amphotericin B, vorico-
nazole, or combination treatment). Variables with a p-value of
<0.1 by univariate analysis were entered into the multivariable
analysis, and variables with a p-value of <0.05 weremaintained in
the ﬁnal model.
Categorical variables were compared by use of the
chi-square or Fisher exact test as appropriate, and continuous
variables were compared by use of the Wilcoxon test. Kaplan–
Meier curves were constructed and compared by use of the
log-rank test. p-Values of <0.05 were considered to be
statistically signiﬁcant, and all statistical tests were performed
with SPSS software (SPSS, version 16.0; SPSS, IBM Inc., New
York, NY, USA).
Results
A total of 233 cases were recorded from 44 centres in 11
countries: Brazil (n = 124), the USA (n = 69), Germany
(n = 13), Canada, Italy and India (ﬁve each), France (n = 4),
Turkey (n = 3), Austria (n = 2), Switzerland, England, and
Denmark (one each). There were 121 cases diagnosed in
period 1 (1985–2000) and 112 in period 2 (2001–2011).
Table 1 shows the baseline characteristics of patients.
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Species identiﬁcation was available locally in 49 of the 233
cases (23%). F. solani species complex was the most frequent
agent (n = 29), followed by F. oxysporum species complex
(n = 7), Fusarium incarnatum and Fusarium proliferatum (three
cases each), Fusarium verticillioides (n = 3), and Fusarium dime-
rum, Fusarium sacchari, F. solani + Fusarium antophilium and
Fusarium sporotrichoides (one case each).
Skin involvement was observed in 61% of patients, and its
frequency did not differ over the two periods (58% in period 1
and 65% in period 2, p 0.25; Table 2). Detailed information on
the diagnostic method was available in 224 of the 233 cases.
The diagnosis was made by culture alone in 138 cases, culture
plus histopathology in 83, and histopathology alone in three
(probable fusariosis). The skin was the most frequent source
of diagnosis (100 cases), followed by the blood (85 cases).
Histopathological conﬁrmation of disease was more frequent
in period 2 (47 vs. 29%, p 0.006).
A total of 206 patients (88%) received treatment for
fusariosis, with a higher proportion of patients receiving
treatment in period 2 (93 vs. 84%, p 0.04). The most frequent
drug used as primary treatment was deoxycholate amphoter-
icin B (47%), followed by voriconazole monotherapy (16%),
and a lipid formulation of amphotericin B monotherapy (15%).
Combination therapy was used in 21 patients: voriconazole
plus a lipid formulation of amphotericin B (n = 12), plus
deoxycholate amphotericin B (n = 5), plus terbinaﬁne (n = 2),
and a lipid formulation of amphotericin B plus posaconazole
(n = 2). On comparison of the two periods, there was a
signiﬁcant reduction in the use of deoxycholate amphoteri-
cin B as primary treatment and an increase in the use of
voriconazole and combination therapy (Table 2). After period
had been controlled for, primary treatment did not differ
signiﬁcantly by centre or country.
The primary treatment regimen was modiﬁed in 47 of the
206 patients (23%) who received treatment: 8% in period 1
and 37% in period 2 (p <0.001). The most frequent reason for
change in the primary treatment regimen was no response
(38%), followed by renal toxicity (21%, all with deoxycholate
amphotericin B).
As shown in Fig. 1, the 90-day probabilities of survival were
43% in period 2 and 22% in period 1 (p <0.001). Fig. 2 shows
the 90-day probability of survival in period 2 by primary
treatment: the 90-day survival rates were 60% with vorico-
TABLE 1. Baseline characteristics of 233 patients with inva-
sive fusariosis
Characteristic
Total,
N = 233
Period 1,
N = 121
Period 2,
N = 112 p-Value
Gender: male/female 147 : 86 68 : 53 79 : 33 0.02
Age (years), median
(range)
39.5 (2–76) 33 (2–76) 44 (3–75.5) 0.003
Underlying disease
Haematological
disease
215 (92) 115 (95) 100 (89) 0.10
Acute myeloid
leukaemia
91 (39) 44 (36) 47 (42)
Acute lymphoid
leukaemia
46 (20) 22 (18) 24 (21)
Chronic myeloid
leukaemia
22 (9) 18 (15) 4 (4)
Myelodysplastic
syndrome
13 (6) 8 (7) 5 (4)
Aplastic anaemia 13 (6) 7 (6) 6 (5)
Non-Hodgkin
lymphoma
11 (5) 7 (6) 4 (4)
Multiple myeloma 10 (4) 5 (4) 5 (4)
Myeloﬁbrosis 1 (1) – 1 (1)
Solid tumour 6 (3) 2 (2) 4 (4)
Solid organ
transplantationa
3 (1) 1 (1) 2 (2)
Otherb 9 (4) 3 (2) 6 (5)
HCT 104 (45) 62 (51) 42 (37) 0.03
Autologous 15/104 (14) 7/62 (11) 8/42 (19)
Allogeneic 89/104 (86) 55/62 (89) 34/42 (81)
Donor relatedness
Related 57/89 (64) 36/55 (65) 21/34 (62) 0.72
Unrelated 32/89 (36) 19/55 (34) 13/34 (38)
HLA match
Matched 83/89 (93) 50/55 (91) 33/34 (97) 0.40
Mismatched 6/89 (7) 5/55 (9) 1/34 (3)
Acute GVHD III/IV 21/89 (24) 15/55 (27) 6/34 (18) 0.30
Chronic extensive
GVHD
11/89 (12) 8/55 (14) 3/34 (9) 0.52
Receipt of
corticosteroidsc
119/228 (52) 56/116 (48) 63/112 (56) 0.23
Neutropenia at
diagnosis of fusariosis
176 (75) 80 (66) 96 (86) 0.001
Neutropenia at
end of treatment
88 (38) 51 (42) 37 (33) 0.15
Numbers in parentheses represent percentages unless otherwise speciﬁed.
GVHD, graft-versus-host disease; HCT, haematopoietic cell transplantation; HLA,
human leukocyte antigen.
aSolid organ transplantation: kidney (three patients).
bOther underlying diseases: multiple sclerosis (three patients), diabetes, asthma,
stroke, hepatitis B, chronic use of corticosteroids, and leukodystrophy (one
patient each).
cInformation not available for ﬁve patients.
TABLE 2. Clinical manifestations and treatment of 233
patients with invasive fusariosis
Characteristic
Total,
N = 233
Period 1,
N = 121
Period 2,
N = 112 p-Value
Skin involvement 143 (61) 70 (58) 73 (65) 0.25
Lung involvement 114 (49) 60 (50) 54 (48) 0.83
Sinusitis 72 (31) 34 (28) 38 (34) 0.34
Fungaemia 86 (37) 31 (26) 55 (49) <0.001
Disseminated disease 166 (72) 89 (74) 77 (69) 0.48
Received treatment 206 (88) 102 (84) 104 (93) 0.04
Deoxycholate
amphotericin B
110 (47) 76 (63) 34 (30) <0.001
Lipid formulation
of amphotericin Ba
34 (15) 22 (18) 12 (11) 0.11
Voriconazole 38 (16) 2 (2) 36 (32) <0.001
Combination therapyb 21 (9) 1 (1) 20 (18) <0.001
Otherc 3 (1) 1 (1) 2 (2)
Receipt of G-CSF
or GM-CSFd
106 (47) 45 (37) 59 (53) 0.02
Granulocyte transfusiond 28 (12) 20 (16) 8 (7) 0.03
Numbers in parentheses represent percentages.
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–monocyte
colony-stimulating factor.
aLipid formulation of amphotericin B: liposomal amphotericin B (n = 20; 11 in
period 1 and nine in period 2), amphotericin B lipid complex (n = 8; six in period
1 and two in period 2), and amphotericin B colloidal dispersion (n = 6; ﬁve in
period 1 and one in period 2).
bCombination therapy consisted of voriconazole (19 cases) plus liposomal
amphotericin B (n = 10), deoxycholate amphotericin B (n = 5), amphotericin B
lipid complex (n = 2) and terbinaﬁne (n = 2), and posaconazole plus liposomal
amphotericin B (n = 1).
cOther treatment: itraconazole (one case, period 1), posaconazole and surgery
(one case each, period 2).
dAfter the diagnosis of fusariosis.
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nazole (95% CI 52–68), 53% with a lipid formulation of
amphotericin B (95% CI 37–72), and 28% with deoxycholate
amphotericin B (95% CI 20–36) (p 0.04; log-rank test for
trend). In the assessment of prognostic factors, variables not
signiﬁcant by univariate analysis were age, gender, country,
presence and severity of GVHD, neutropenia at diagnosis of
fusariosis, clinical presentation, and primary treatment with a
lipid formulation of amphotericin B or with combination
therapy. As shown in Table 3, the variables signiﬁcantly
associated with poor prognosis (death 90 days after the
diagnosis of fusariosis) by multivariable analysis were: receipt
of corticosteroids (hazard ratio (HR) 2.11, 95% CI 1.18–3.76,
p 0.01), neutropenia at end of treatment (HR 2.70,
95% CI 1.57–4.65, p <0.001), and receipt of deoxycholate
amphotericin B (HR 1.83, 95% CI 1.06–3.16, p 0.03).
Discussion
To the best of our knowledge, this is the largest series of cases
of IF ever reported, with data being collected by investigators
from 11 countries. We conﬁrmed our hypothesis that the
outcome of IF has improved in the last decade. We also
conﬁrmed that two host factors, i.e. receipt of corticosteroids
and persistent neutropenia, are important predictors of poor
outcome. In addition, we observed important changes in
therapeutic practices, with a reduction in the use of deoxy-
cholate amphotericin B and an increase in the use of voric-
onazole and combination therapy. Finally, primary treatment
with either voriconazole or a lipid formulation of amphoter-
icin B was associated with better outcome, whereas deoxy-
cholate amphotericin B primary treatment was associated with
poor outcome.
Overall, the clinical presentation of IF was not different in
the two periods. Fungaemia was more common in period 2,
possibly as a reﬂection of improvements in blood culture
systems and media. The diagnostic practices did not change
substantially over time, with the exception of a higher
proportion of patients with a histopathological diagnosis in
period 2. Clinicians might have become more aware of the
typical clinical presentation of IF in severely immunosup-
pressed haematological patients [7], and the importance of
obtaining tissue (mostly biopsy of skin lesions) to establish the
diagnosis as early as possible. This could have contributed to
the improved survival observed in period 2.
The most striking difference between periods 1 and 2 was
in the choice of primary treatment regimen, with a reduction
in the use of deoxycholate amphotericin B and an increase in
voriconazole and combination therapy (voriconazole in all but
FIG. 1. Probability of 90-day survival of 233 patients with invasive
fusariosis in period 1 (1985–2000) and period 2 (2001–2011).
FIG. 2. Probability of 90-day survival of 83 patients with invasive
fusariosis in period 2 treated with deoxycholate amphotericin B
(d-AMB), voriconazole, or a lipid formulation of amphotericin B (Lipid
AMB).
TABLE 3. Factors associated with poor outcome (death
90 days after diagnosis) in 206 patients with invasive fusariosis
who received treatment
Variable
Unadjusted Adjusted
HR (95% CI) p HR (95% CI) p
Haematological disease 5.70 (0.79–41.24) 0.08 5.26 (0.71–38.73 0.11
Receipt of
corticosteroids
2.21 (1.24–3.94) 0.007 2.11 (1.18–3.76) 0.01
Neutropenia at end
of treatment
2.61 (1.52–4.46) <0.001 2.70 (1.57–4.65) <0.001
Disseminated disease 1.72 (0.90–3.26) 0.09 1.45 (0.72–2.94) 0.30
Primary treatment with
deoxycholate
amphotericin Ba
1.75 (1.02–3.01) 0.04 1.83 (1.06–3.16) 0.03
Primary treatment with
voriconazolea
0.61 (0.34–1.11) 0.09 0.77 (0.38–1.55) 0.47
HR, hazard ratio.
aAs a single agent. Neither lipid amphotericin B (HR 0.67, 95% CI 0.27–1.69) or
combination therapy (HR 1.20, 95% CI 0.63–2.28) was signiﬁcant by univariate
analysis.
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one case). This increased use of voriconazole in primary
treatment (especially monotherapy) is of particular interest,
because in vitro data indicate that most Fusarium speceis
(especially F. solani, the most frequent agent of IF) show high
MICs for voriconazole [1,8,9]. In a previous study, the MIC
range and geometric mean of 22 F. solani and 14 F. oxysporum
isolates were 4–16 mg/L and 14 mg/L, and 0.5–16 mg/L and
4 mg/L, respectively. By contrast, amphotericin B showed
better in vitro activity, with geometric means of 1.33 mg/L for
F. solani and 0.78 mg/L for F. oxysporum [10]. Therefore, even
though we acknowledge that a correlation between MIC and
outcome has not been evaluated in IF, we would expect
clinicians to choose a lipid formulation of amphotericin B as
primary treatment, as generally recommended [11]. In our
study, information on in vitro susceptibility was available for
only 20 patients. Furthermore, as we did not have information
on the laboratory procedures for MIC assessment in the
different centres, we did not analyse the correlation between
in vitro data and outcome.
The improvement in outcome of IF in period 2 may be a
reﬂection of better management of the underlying disease,
including supportive care and primary treatment [12,13].
Because of these potential differences in patient care in
periods 1 and 2, we decided to evaluate prognostic factors only
in period 2. Our multivariable analysis conﬁrmed the inﬂuence
of host factors (persistent neutropenia and receipt of corticos-
teroids) as strong predictors of poor outcome in IF [2,3]. The
other signiﬁcant variable was primary treatment with deoxych-
olate amphotericin B. By contrast, although receipt of vorico-
nazole or a lipid formulation of amphotericin B as primary
treatment was not signiﬁcant in the multivariable analysis, the
outcome with these drugs was better (60% and 53%, respec-
tively) than with deoxycholate amphotericin B (28%). This 60%
90-day survival with voriconazole monotherapy as ﬁrst-line
treatment is remarkable, and contrasts with in vitro antifungal
susceptibility tests, which consistently show high MICs with the
majority of Fusarium species [10].
Our study shares the limitations of other retrospective
studies. Although we were successful in merging four
databases, data on some important variables were not available
for all patients, including the status of the underlying disease,
recent chemotherapeutic regimen, dose of corticosteroids,
duration of neutropenia, pattern of lung involvement, portal of
entry, and dose of antifungal treatment. However, by renounc-
ing completeness, we were able to collect a large number of
patients with IF. In addition, none of the variables included in
the Cox regression analysis of predictors of poor outcome had
missing values. Another potential limitation is that we did not
have information on changes in patient care that could have
inﬂuenced the results favouring period 2, such as improve-
ments in the management of the underlying conditions and
different doses of corticosteroids for the management of
GVHD.
Despite these limitations, our ﬁndings have important
implications. First, as host factors are important prognostic
factors, a great effort should be made to minimize and/or
abbreviate immunosupprion, including neutropenia and the use
of corticosteroids. Second, considering the good response
with voriconazole as ﬁrst-line treatment, this drug should be
added to a lipid formulation of amphotericin B as an option in
the primary treatment of IF. Finally, studies are needed to
determine whether there is any correlation between MIC and
outcome.
In conclusion, therapeutic practices have changed substan-
tially over the last decade, with a decrease in the use of
deoxycholate amphotericin B and an increase in voriconazole
and combination therapy. The outcome of IF has signiﬁcantly
improved in the last decade.
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